Finally, the deletion of MAP3K7, also referred to as TAK1, reduced the expression of HR proteins and was shown to sensitize prostate cancer cells to the multi-CDK inhibitor dinaciclib or Olaparib [141]. Here, MAP3K7 is linked to prostate cancer.